Figure 3. IL-6 (A) and S-100 protein (B) plasma levels in placebo (white) and QH treated patients (grey) at phase 1, 3 and 4. ** p≤0.01, #p≤0.05 and ##p≤0.01 significance of differences in each experimental group in comparison with phase 1 (a) and 3 (b).